Jinwon Life Sciences Selected as Priority Negotiator for National COVID-19 Vaccine Project
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 30th that it has been selected as the priority negotiation candidate for the Disease Control Headquarters' urgent academic research and development project titled ‘Development of COVID-19 Vaccine Candidates Using a Nucleic Acid Vaccine Platform’ this year.
The Disease Control Headquarters plans to rapidly develop COVID-19 vaccine candidates using a nucleic acid vaccine platform domestically through this national project, as the international public-private organization Coalition for Epidemic Preparedness Innovations (CEPI) includes support for vaccine candidate research using DNA and mRNA in its rapid COVID-19 vaccine development project, and the U.S. National Institutes of Health (NIH) has also initiated nucleic acid vaccine-based research.
A GeneOne Life Science official stated, “Using a two-track strategy with our company’s DNA vaccine platform and mRNA vaccine platform specialized for emerging infectious disease vaccines, we have been designing and producing vaccine candidates since immediately after the first confirmed COVID-19 case in Korea,” and added, “With our selection as the priority negotiator for this national project, we plan to collaborate with domestic and international specialized research institutions and university research teams to evaluate the vaccine immune response induction ability of each vaccine candidate and assess COVID-19 virus prevention efficacy through animal experiments.”
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Park Young-geun, CEO of GeneOne Life Science, emphasized, “As the development of a COVID-19 vaccine is urgent in Korea, our company, as a specialized emerging infectious disease vaccine developer, applied for this national project to fulfill our role and promote the development of a domestically self-sufficient COVID-19 vaccine together with the government,” and added, “Based on global clinical experience with MERS and Zika vaccines, we will carry out the rapid and successful development of the COVID-19 vaccine.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
